Foundation Health and Wellness
- IV Therapy
- IV Hydration
- Acne Treatment
- Peptide Therapy
- Erectile Dysfunction (ED) Treatment
Albuquerque, NM
Albuquerque has a smaller but active integrative medicine market with full NP practice authority widely used, and peptide therapy has grown into a visible slice of the local wellness market. The clinics we track across Nob Hill, the Northeast Heights, and Rio Rancho range from physician-led longevity practices to medspa-adjacent wellness offices offering sermorelin blends and growth hormone peptides. Most local prescribers have training or admitting privileges within the UNM Hospital, Presbyterian, and Lovelace network. The scene here skews toward NP-led wellness clinics serving a cost-conscious but longevity-curious population. The regulatory landscape shifted sharply in 2023 and 2024 when the FDA placed several widely prescribed peptides on its Category 2 bulk substances list, restricting which ingredients compounding pharmacies could legally source. That changed access overnight for BPC-157, CJC-1295, ipamorelin, and thymosin beta-4. Sermorelin and tesamorelin remain FDA-approved for specific indications, and reputable Albuquerque clinics now draw a clearer line between approved peptides and off-label research compounds than they did two years ago.
Regulatory context
Most research peptides used in regenerative medicine (BPC-157, TB-500, CJC-1295, ipamorelin) are not FDA-approved drugs. Sermorelin and tesamorelin hold FDA approvals for specific indications. The FDA placed several peptides into Category 2 on its Bulk Drug Substances Nominated for Use in Compounding list during 2023 and 2024, restricting 503A pharmacy sourcing. Section 503A covers traditional patient-specific compounding; Section 503B covers FDA-registered outsourcing facilities held to cGMP.
The New Mexico Board of Pharmacy inspects compounding pharmacies for USP 795 and USP 797 compliance. Non-resident pharmacies shipping peptides into New Mexico must hold a current non-resident pharmacy license. The Board publishes disciplinary actions.